Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.
Latest SPAC News: GreenLight Biosciences returns to private market, Jet.AI partners with Vegas Golden Knights and Cirrus Aviation, and True Velocity announces partnership with FN America
GreenLight returns to private market in $46M deal after taste of Wall Street
GreenLight Biosciences will seek its dream off Wall Street in a go-private deal less than two years after taking the special purpose acquisition company route there.
The company is returning to private life in a $45.5 million all-cash deal from a coalition led by Fall Line Capital, according to a Tuesday relaease. The agreement comes two months after GreenLight first disclosed that Fall Line was interested in scooping up the faltering RNA biotech. The deal was unanimously agreed upon by GreenLight’s board of directors.
JET.AI Partners With Vegas Golden Knights And Cirrus Aviation To Provide Fans With By-The-Seat Private Jet Experience To Away Games
Jet Token Inc. d/b/a Jet.AI, an innovative private aviation, artificial intelligence, booking and membership platform and Cirrus Aviation, a leading private jet provider, have announced an official partnership with the Vegas Golden Knights to provide fans the ultimate private aviation experience for away games.
This partnership comes on the heels of Jet.AI’s recent announcement of a proposed business combination with Oxbridge Acquisition Corp. (NASDAQ: OXAC).
True Velocity Partners with FN America to Develop M240 Conversion Kit
Texas-based advanced technology company TV Ammo, Inc. announced today a strategic development partnership with FN America that would enable one of the most prolific machine guns in the world to fire its proprietary 6.8TVCM composite-cased cartridge.
As previously announced on November 1, 2022, TV Ammo, Inc. entered into a business combination agreement with Breeze Holdings Acquisition Corp. (NASDAQ: BREZ).
READAUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer
AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision oncology therapeutics, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating AUM001 for the treatment of metastatic colorectal cancer (MSS CRC). AUM001 is a mRNA translation inhibitor that targets MNK 1/2 and the chokepoint of multiple pro-oncogenic signalling pathways for the treatment of MSS CRC.
As previously announced on October 20, 2022, AUM entered into a definitive business combination agreement with Mountain Crest Acquisition Corp. V (Nasdaq: MCAG).
READ
At the SPAC of Dawn September’s busy, but short, first week is set to keep rolling with three completion votes by Achari I (OTC:AVHI), Nova Vision (NASDAQ:NOVV) and Focus Impact (NASDAQ:FIAC) this week. All three of these have been postponed at least once, and could do so again, but Focus Impact has its transaction deadline...
Terms Tracker for the Week Ending September 6, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. It was a short holiday week and while it was light on filings, SPACs did manage to price two IPOs. That means 2024 has now...
Compass Digital (NASDAQ:CDAQ) has entered into a definitive agreement to combine with renewable energy firm EEW at a pro forma enterprise value of $386 million. London-based EEW is a solar, hydrogen and energy storage project developer with 1.4 GW of solar projects sold to date in Australia, the UK, Spain, and Sweden. The combined company...
Evergreen (NASDAQ:EVGR) has entered into a definitive agreement to combine with enterprise software firm Forekast at a pre-money enterprise value of $105 million. The company provides data analytics and customer engagement tools backed by some degree of AI automation to improve efficiencies for its business clients. The combined company is expected to trade on the...
At the SPAC of Dawn The auto-reply messages are off. SPACs are definitively back from vacation and in the thick of it. Two new SPACs are set to debut in trading today in Vine Hill (NASDAQ:VCICU) and Andretti II (NASDAQ:POLEU) and two SPACs have also landed their search on new targets, which could pull a...